Various clinical trials in the last decade have even advocated the use of these AIs in an earlier clinical setting for treating primary breast cancer.12–18 However, inhibition of aromatase is not the only strategy available for decreasing the production of oestrogens. This evidence concerns the gene CYP19A1 and breast carcinoma.